Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.

[1]  Yi-long Wu,et al.  Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells , 2013, PloS one.

[2]  William Pao,et al.  Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Edward S. Kim,et al.  Epidermal growth factor receptor inhibition in lung cancer: status 2012. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  R. Iglesias-Bartolome,et al.  Exploiting the mTOR paradox for disease prevention , 2012, Oncotarget.

[5]  S. Chellappan,et al.  Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer , 2012, Biochemistry research international.

[6]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[7]  Sung-Liang Yu,et al.  Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Sima,et al.  Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design , 2011, Clinical Cancer Research.

[9]  William Pao,et al.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.

[10]  G. Schatten,et al.  mTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells. , 2010, Cellular reprogramming.

[11]  Ying Wang,et al.  Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. , 2010, The Journal of clinical investigation.

[12]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[13]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[14]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[15]  W. Pao,et al.  Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors , 2007, PloS one.

[16]  T. Veenstra,et al.  Identification of a Highly Effective Rapamycin Schedule that Markedly Reduces the Size, Multiplicity, and Phenotypic Progression of Tobacco Carcinogen–Induced Murine Lung Tumors , 2006, Clinical Cancer Research.

[17]  H. Varmus,et al.  Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.

[18]  J. Tichelaar,et al.  Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model. , 2005, Carcinogenesis.

[19]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[20]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[21]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.